Systematic Comparison of Strategies to Achieve Soluble Expression of Plasmodium falciparum Recombinant Proteins in E. coli

Viability and infectivity of Toxoplasma gondii tachyzoites exposed to Butanedione monoxime

The most important pathogenesis factor in the Apicomplexa parasites is invasion to the host cell. Given the inhibitory role of Butanedione Monoxime (BDM) on myosin-actin interaction, this study aimed to investigate the effects of this molecule on the vitality and infectivity of Toxoplasma tachyzoites in order to provide a new option for vaccine development. The tachyzoites of the RH strain of Toxoplasma gondii were exposed to different concentrations (1, 2, 4, 8, 16, 32, 64, and 128 μg/mL) of BDM, and mortality effect was assessed by flow cytometry. Then, the penetration ability of the tachyzoites was investigated in HeLa and macrophage cell lines. The infectivity of exposed tachyzoites to BDM were also investigated in mice through following up and detecting the etiological factor. The highest percentage of mortality (72.69%) was seen in the tachyzoites exposed to 128 μg/mL of the compound. The tachyzoites exposed to 32, 64, and 128 μg/mL of BDM began the proliferation in HeLa cells after 48 h, while this proliferation was initiated within 24 h in macrophage cells. All the mice inoculated with the BDM-treated tachyzoites died after 13 days. The mean survival time of the mice receiving tachyzoites exposed to 128 μg/mL of BDM was 12.4 days, which was significantly different from the negative control group (p = 0.001). BDM, as the inhibitor of myosin-actin interaction, and other substances that block the entry of parasites into cells may be suitable candidates for vaccine production against Toxoplasma. Yet, future studies are required to be conducted on the issue.

Effect of restricted dissolved oxygen on expression of Clostridium difficile toxin A subunit from E. coli

The repeating unit of the C. difficile Toxin A (rARU, also known as CROPS [combined repetitive oligopeptides]) C-terminal region, was shown to elicit protective immunity against C. difficile and is under consideration as a possible vaccine against this pathogen. However, expression of recombinant rARU in E. coli using the standard vaccine production process was very low. Transcriptome and proteome analyses showed that at restricted dissolved oxygen (DO) the numbers of differentially expressed genes (DEGs) was 2.5-times lower than those expressed at unrestricted oxygen. Additionally, a 7.4-times smaller number of ribosome formation genes (needed for translation) were down-regulated as compared with unrestricted DO. Higher rARU expression at restricted DO was associated with up-regulation of 24 heat shock chaperones involved in protein folding and with the up-regulation of the global regulator RNA chaperone hfq. Cellular stress response leading to down-regulation of transcription, translation, and energy generating pathways at unrestricted DO were associated with lower rARU expression. Investigation of the C. difficile DNA sequence revealed the presence of cell wall binding profiles, which based on structural similarity prediction by BLASTp, can possibly interact with cellular proteins of E. coli such as the transcriptional repressor ulaR, and the ankyrins repeat proteins. At restricted DO, rARU mRNA was 5-fold higher and the protein expression 27-fold higher compared with unrestricted DO. The report shows a strategy for improved production of C. difficile vaccine candidate in E. coli by using restricted DO growth. This strategy could improve the expression of recombinant proteins from anaerobic origin or those with cell wall binding profiles.

Identification of Plasmodium knowlesi Merozoite Surface Protein-119 (PkMSP-119 ) novel binding peptides from a phage display library

OBJECTIVE

Plasmodium knowlesi, the fifth human malaria parasite, has caused mortality in humans. We aimed to identify P. knowlesi novel binding peptides through a random linear dodecapeptide phage display targeting the 19-kDa fragment of Merozoite Surface Protein-1 protein.

METHODS

rPkMSP-1₁₉ protein was heterologously expressed using Expresso^® Solubility and Expression Screening System and competent E. cloni^® 10G cells according to protocol. Three rounds of biopanning were performed on purified rPkMSP-1₁₉ to identify binding peptides towards rPkMSP-1₁₉ using Ph.D.™-12 random phage display library. Binding sites of the identified peptides to PkMSP-1₁₉ were in silico predicted using the CABS-dock web server.

RESULTS

Four phage peptide variants that bound to PkMSP-1₁₉ were identified after three rounds of biopanning, namely Pkd1, Pkd2, Pkd3 and Pkd4. The sequences of both Pkd1 and Pkd2 consist of a large number of histidine residues. Pkd1 showed positive binding signal with 6.1× vs. BSA control. Docking results showed that Pkd1 and Pkd2 were ideal binding peptides for PkMSP-1₁₉ .

CONCLUSION

We identified two novel binding peptides of PkMSP-1₁₉ , Pkd1 (HFPFHHHKLRAH) and Pkd2 (HPMHMLHKRQHG), through phage display. They provide a valuable starting point for the development of novel therapeutics.